SmallCaps Podcast Podcast Por SmallCaps arte de portada

SmallCaps Podcast

SmallCaps Podcast

De: SmallCaps
Escúchala gratis

Market news & in-depth interviews with ASX-listed small cap companies.SmallCaps Podcast Economía Finanzas Personales
Episodios
  • Adherium's Smart Solution for Respiratory Health – A Game Changer?

    Adherium's Smart Solution for Respiratory Health – A Game Changer?
    Feb 12 2026
    In this video, Unknown Host chats with Dawn Bitz, the CEO of Adherium (ADR.ASX), about how their innovative smart jackets are transforming the management of respiratory health. With over 60,000 patients in their insurance-verified funnel, Adherium is leveraging technology to enhance medication adherence and reduce hospitalisations. Dawn shares insights on the company's impressive growth plans, including targeting 10,000 remote patient monitoring (RPM) patients by 2026 through partnerships in the healthcare sector. We discuss Adherium's partnership with the prestigious Intermountain Health system and the groundbreaking data that could redefine adherence metrics and patient outcomes. We also delve into plans for future value-based contracts within the US insurance market. Timestamps: 00:00 - Introduction to Adherium and Dawn Bitz 00:30 - Overview of Adherium’s smart-jacket technology 03:00 - Importance of medication adherence in respiratory health 05:00 - Dawn’s experience meeting with investors 08:00 - RPM revenue model and projections 11:00 - Future plans for scaling RPM and partnerships with Insurers 14:00 - How Adherium is ensuring sustainable growth If you enjoy this content and want to stay updated on Adherium’s developments, make sure to hit that subscribe button and turn on notifications! ⚠️ IMPORTANT DISCLAIMER: This content is for educational and entertainment purposes only and should not be considered financial advice. All investments carry risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consider seeking advice from a qualified financial advisor before making investment decisions. The creator may hold positions in securities discussed. 📌 Articles: https://smallcaps.com.au/australian-market-follows-wall-street-down-market-wrap https://smallcaps.com.au/adherium-partners-astrazeneca-hailie-smartinhaler-clinical-trial https://smallcaps.com.au/adherium-hailie-smartinhaler-fda-approval-astrazeneca-devices https://smallcaps.com.au/adherium-us-health-group-remote-medical-management-high-risk-respiratory-patients https://smallcaps.com.au/adherium-receives-fda-grant-market-smartinhaler-us 🔎 More on Adherium: https://smallcaps.com.au/stocks/asx-adr/ ⸻ Small Caps is Australia’s #1 site for market news & information on ASX-listed small cap companies. 🌐 WEBSITE https://smallcaps.com.au/ 🎧 PODCAST https://smallcaps.com.au/podcast/ 📱 SOCIAL MEDIA Facebook: https://www.facebook.com/SmallCapsASX Twitter: https://twitter.com/SmallCapsASX LinkedIn: https://www.linkedin.com/company/small-caps/ 📬 NEWSLETTER https://smallcaps.com.au/subscribe/
    Más Menos
    Menos de 1 minuto
  • How Adherium is Revolutionising Respiratory Health Care

    How Adherium is Revolutionising Respiratory Health Care
    Feb 12 2026
    In this video, Unknown Host sits down with Dawn Bitz, CEO of Adherium, to explore the innovative approaches the company is using to tackle respiratory health issues. Adherium, a leader in digital health technology, has developed smart-adherence jackets that track medication usage for patients with respiratory diseases like asthma and emphysema. These jackets are designed to improve medication compliance through sophisticated sensors, ultimately aiming to reduce hospitalisation rates and healthcare costs. Dawn shares insights from a recent partnership with Intermountain Health, showcasing impressive data that underlines the effectiveness of their technology in improving patient outcomes. With the goal of expanding their remote patient monitoring revenue model and targeting 10,000 RPM patients by 2026, Adherium’s story is one of innovation and potential growth in the healthcare sector. Timestamps: 00:00 - Introduction 00:45 - Overview of Adherium 02:15 - The impact of respiratory diseases 04:30 - Key innovations in medication usage 06:00 - Partnership with Intermountain Health 08:15 - Revenue models and future targets 10:00 - Scaling operations and targets for 2026 12:00 - Conclusion If you're interested in understanding how technology is changing health care, make sure you subscribe and turn on notifications for more insights from leaders in the small-cap sector. ⚠️ IMPORTANT DISCLAIMER: This content is for educational and entertainment purposes only and should not be considered financial advice. All investments carry risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consider seeking advice from a qualified financial advisor before making investment decisions. The creator may hold positions in securities discussed. 📌 Articles: https://smallcaps.com.au/australian-market-follows-wall-street-down-market-wrap https://smallcaps.com.au/adherium-partners-astrazeneca-hailie-smartinhaler-clinical-trial https://smallcaps.com.au/adherium-hailie-smartinhaler-fda-approval-astrazeneca-devices https://smallcaps.com.au/adherium-us-health-group-remote-medical-management-high-risk-respiratory-patients https://smallcaps.com.au/adherium-receives-fda-grant-market-smartinhaler-us 🔎 More on Adherium: https://smallcaps.com.au/stocks/asx-adr/ ⸻ Small Caps is Australia’s #1 site for market news & information on ASX-listed small cap companies. 🌐 WEBSITE https://smallcaps.com.au/ 🎧 PODCAST https://smallcaps.com.au/podcast/ 📱 SOCIAL MEDIA Facebook: https://www.facebook.com/SmallCapsASX Twitter: https://twitter.com/SmallCapsASX LinkedIn: https://www.linkedin.com/company/small-caps/ 📬 NEWSLETTER https://smallcaps.com.au/subscribe/
    Más Menos
    Menos de 1 minuto
  • 2026 Is Really Our Transformational Year

    2026 Is Really Our Transformational Year
    Feb 11 2026
    In this video, Dawn Bitz, CEO of Adherium, discusses how their innovative respiratory remote patient monitoring (RPM) platform is revolutionising healthcare for patients with respiratory conditions. Adherium has developed smart-jacket sensors that enhance medication adherence, significantly improving patient outcomes and reducing hospitalisation costs. With impressive data from their collaboration with Intermountain Health, including a 235% improvement in adherence, Dawn shares key insights on how their technology is designed to benefit both patients and healthcare providers. Join us as we break down the technology, the business strategy, and the future prospects of Adherium, targeting an ambitious growth in RPM patients by 2026. Whether you're an investor or just curious about healthcare innovations, this is a must-watch. **Timestamps:** 00:00 Introduction to Dawn Bitz 00:12 Overview of Adherium's role in healthcare 00:42 The importance of medication adherence 01:30 The smart-jacket technology explained 02:00 How it works for patient data collection 02:30 Cost reductions through adherence 03:10 Key insights from the partnership with Intermountain Health 03:50 Future growth plans and targets for 2026 04:30 Closing thoughts and what’s next for Adherium Stay tuned for more updates on how Adherium is making a real change in patient care. Don't forget to like, share, and subscribe for the latest in ASX small-cap news! ⚠️ IMPORTANT DISCLAIMER: This content is for educational and entertainment purposes only and should not be considered financial advice. All investments carry risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consider seeking advice from a qualified financial advisor before making investment decisions. The creator may hold positions in securities discussed. 📌 Articles: https://smallcaps.com.au/australian-market-follows-wall-street-down-market-wrap https://smallcaps.com.au/adherium-partners-astrazeneca-hailie-smartinhaler-clinical-trial https://smallcaps.com.au/adherium-hailie-smartinhaler-fda-approval-astrazeneca-devices https://smallcaps.com.au/adherium-us-health-group-remote-medical-management-high-risk-respiratory-patients https://smallcaps.com.au/adherium-receives-fda-grant-market-smartinhaler-us 🔎 More on Adherium: https://smallcaps.com.au/stocks/asx-adr/ ⸻ Small Caps is Australia’s #1 site for market news & information on ASX-listed small cap companies. 🌐 WEBSITE https://smallcaps.com.au/ 🎧 PODCAST https://smallcaps.com.au/podcast/ 📱 SOCIAL MEDIA Facebook: https://www.facebook.com/SmallCapsASX Twitter: https://twitter.com/SmallCapsASX LinkedIn: https://www.linkedin.com/company/small-caps/ 📬 NEWSLETTER https://smallcaps.com.au/subscribe/
    Más Menos
    Menos de 1 minuto
Todavía no hay opiniones